An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 28 Jul 2017 Planned End Date changed from 1 Dec 2017 to 7 Mar 2018.
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.